Nothing Special   »   [go: up one dir, main page]

NO993646D0 - Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity - Google Patents

Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity

Info

Publication number
NO993646D0
NO993646D0 NO993646A NO993646A NO993646D0 NO 993646 D0 NO993646 D0 NO 993646D0 NO 993646 A NO993646 A NO 993646A NO 993646 A NO993646 A NO 993646A NO 993646 D0 NO993646 D0 NO 993646D0
Authority
NO
Norway
Prior art keywords
obesity
agonists
diabetes
beta
treatment
Prior art date
Application number
NO993646A
Other languages
Norwegian (no)
Other versions
NO993646L (en
Inventor
Robert J Mathvink
Emma R Parmee
Samuel Tolman
Ann E Weber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO993646D0 publication Critical patent/NO993646D0/en
Publication of NO993646L publication Critical patent/NO993646L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO993646A 1997-01-28 1999-07-27 Thiazolebenzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity NO993646L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
PCT/US1998/001317 WO1998032753A1 (en) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Publications (2)

Publication Number Publication Date
NO993646D0 true NO993646D0 (en) 1999-07-27
NO993646L NO993646L (en) 1999-09-27

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993646A NO993646L (en) 1997-01-28 1999-07-27 Thiazolebenzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity

Country Status (22)

Country Link
EP (1) EP0968209A1 (en)
JP (1) JP2001509166A (en)
KR (1) KR20000070568A (en)
CN (1) CN1251099A (en)
AR (1) AR011092A1 (en)
AU (1) AU728812B2 (en)
BG (1) BG103686A (en)
BR (1) BR9807096A (en)
CA (1) CA2278739A1 (en)
EA (1) EA199900692A1 (en)
EE (1) EE9900328A (en)
HR (1) HRP980044A2 (en)
HU (1) HUP0002053A3 (en)
ID (1) ID22273A (en)
IL (1) IL131130A0 (en)
IS (1) IS5131A (en)
NO (1) NO993646L (en)
PE (1) PE52299A1 (en)
PL (1) PL334833A1 (en)
SK (1) SK100099A3 (en)
TR (1) TR199902442T2 (en)
WO (1) WO1998032753A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (en) * 1998-05-29 1999-12-02 Novartis Ag Amino azole compounds
PT1741445E (en) 2000-01-21 2013-11-11 Novartis Ag Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
PT1138685E (en) 2000-03-31 2004-08-31 Pfizer Prod Inc PROCESS FOR THE PREPARATION OF REPLACED PYRIDINES
KR20030016396A (en) 2000-07-13 2003-02-26 일라이 릴리 앤드 캄파니 Beta3 adrenergic agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6825220B2 (en) 2000-11-10 2004-11-30 Eli Lilly And Company 3-Substituted oxindole β 3 agonists
DE60139639D1 (en) 2000-12-08 2009-10-01 Takeda Pharmaceutical SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE
AR035605A1 (en) 2000-12-11 2004-06-16 Bayer Corp DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS
AR035858A1 (en) 2001-04-23 2004-07-21 Bayer Corp CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS
ATE316088T1 (en) * 2001-06-22 2006-02-15 Merck & Co Inc TYROSINE KINASE INHIBITORS
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
US6911463B2 (en) 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
EP1435951B1 (en) * 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
JP2005514366A (en) 2001-11-20 2005-05-19 イーライ・リリー・アンド・カンパニー 3-Substituted oxindole β3 agonist
US7071208B2 (en) 2001-11-20 2006-07-04 Eli Lilly And Company β3 Adrenergic agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
WO2006132196A1 (en) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
CN101277960A (en) 2005-09-29 2008-10-01 默克公司 Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1937264B1 (en) * 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (en) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Guanylate cliclas agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2531501B1 (en) 2010-02-03 2013-11-20 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201690035A1 (en) 2011-02-25 2016-05-31 Мерк Шарп Энд Домэ Корп. NEW CYCLIC DERIVATIVES OF AZABENZIMIDAZOLE, USED AS ANTI-DIABETIC AGENTS
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
ES2394349B1 (en) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN104994848A (en) 2013-02-22 2015-10-21 默沙东公司 Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PT3004138T (en) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL131130A0 (en) 2001-01-28
ID22273A (en) 1999-09-23
HUP0002053A2 (en) 2001-08-28
CA2278739A1 (en) 1998-07-30
WO1998032753A1 (en) 1998-07-30
PL334833A1 (en) 2000-03-27
JP2001509166A (en) 2001-07-10
TR199902442T2 (en) 2000-07-21
EA199900692A1 (en) 2000-02-28
NO993646L (en) 1999-09-27
HRP980044A2 (en) 1998-10-31
PE52299A1 (en) 1999-05-26
BG103686A (en) 2000-06-30
CN1251099A (en) 2000-04-19
SK100099A3 (en) 2000-05-16
AR011092A1 (en) 2000-08-02
AU6038498A (en) 1998-08-18
EP0968209A1 (en) 2000-01-05
AU728812B2 (en) 2001-01-18
BR9807096A (en) 2000-04-18
KR20000070568A (en) 2000-11-25
HUP0002053A3 (en) 2001-09-28
IS5131A (en) 1999-07-23
EE9900328A (en) 2000-02-15

Similar Documents

Publication Publication Date Title
NO993646D0 (en) Thiazole benzenesulfonamides as &lt;beta&gt; 3 agonists for the treatment of diabetes and obesity
NO964548D0 (en) Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity
NO20006630D0 (en) Pharmaceutical composition for the treatment of diabetes
AU3723297A (en) Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
GB9619331D0 (en) Selective ›3 agonists for the treatment of diabetes and obesity
DZ2936A1 (en) New modified release composition for the treatment of diabetes.
NO976063D0 (en) Procedure for the treatment of diabetes
NO308131B1 (en) Hypolipidemic 1,4-benzothiazepine-1,1-dioxides, their use and pharmaceutical composition
DK1206457T3 (en) Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs
NO961432D0 (en) Benzophiophenes and related compounds as estrogen agonists
DK0996444T3 (en) Treatment of diabetes with thiazolidinedione and metformin
AU3374897A (en) Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
ZA953336B (en) Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
NO972451D0 (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof
NO20001914D0 (en) &lt;alfa&gt; -Aryl-N-alkylnitrons and pharmaceutical compositions containing them
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
NO20022087D0 (en) Procedure for the treatment of diabetes
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
IT1294080B1 (en) PROCEDURE AND APPARATUS FOR THE EXTERNAL INSPECTION OF CONTAINERS.
DE69432116D1 (en) Ceramic composition and thermistor containing this ceramic composition
FI941776A0 (en) Process for the preparation of 1,2,4-thiadiazoles
DE69610602D1 (en) Antiferroelectric liquid crystal compound and antiferroelectric liquid crystal composition
NO996467D0 (en) Process for the preparation of thiazofurine and other C-nucleosides
NO20000229D0 (en) Treatment of diabetes with thiazolidinedione and sulfonylurea
NO996264D0 (en) Treatment of diabetes with thiazolidinedione and sulfonylurea

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application